SGT-53 + gemcitabine + nab-paclitaxel

**SGT-53 + gemcitabine + nab-paclitaxel** is an experimental **combination therapy** aimed at treating advanced and metastatic solid tumors, notably including pancreatic cancer. - **SGT-53** is a tumor-targeted, liposomal nanocomplex engineered to deliver wild-type p53 gene specifically to cancer cells, utilizing an anti-transferrin receptor single-chain antibody fragment for targeting. Its mechanism involves reconstituting p53 tumor suppressor function, thereby enhancing tumor cell apoptosis, increasing tumor immunogenicity, and sensitizing tumors to damage inflicted by chemotherapy or immunotherapy[1][3][7]. - **Gemcitabine** is a cytidine analog that inhibits DNA synthesis, acting as an antimetabolite antineoplastic agent[4][6]. - **Nab-paclitaxel** (albumin-bound paclitaxel, Abraxane) is a microtubule inhibitor chemotherapy delivered as a nanoparticle albumin-bound formulation, which improves delivery and may reduce hypersensitivity compared to solvent-based paclitaxel[4]. - The triple regimen is being assessed to exploit synergistic effects: restoration of p53 increases chemosensitivity and immunogenicity, while gemcitabine and nab-paclitaxel deliver established cytotoxic activity[1][3]. - The main developer of SGT-53 is **SynerGene Therapeutics**[7]. - Nab-paclitaxel (Abraxane) is manufactured by **Bristol Myers Squibb**; gemcitabine’s main manufacturers include **Eli Lilly** and various generics.

Other names

nab-paclitaxelpaclitaxel albumin-boundgemcitabine